drugset / Trial / NCT01775358
Phase 1 Safety Study of ALRN-5281 in Healthy Subjects
RandomizedSingle-groupSingle-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of a single dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers.
Timeline
- Start
- 2013-01
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALRN-5281 | Unknown | 0.015 mg/kg | Subcutaneous |
| Subject | ALRN-5281 | Unknown | 0.05 mg/kg | Subcutaneous |
| Subject | ALRN-5281 | Unknown | 0.15 mg/kg | Subcutaneous |